Justine OMalley - Protara Therapeutics Senior Affairs
| TARA Stock | USD 2.39 0.10 4.37% |
Executive
Justine OMalley is Senior Affairs of Protara Therapeutics
| Address | 345 Park Avenue South, New York, NY, United States, 10010 |
| Phone | 646 844 0337 |
| Web | https://www.protaratx.com |
Protara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2811) % which means that it has lost $0.2811 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4591) %, meaning that it created substantial loss on money invested by shareholders. Protara Therapeutics' management efficiency ratios could be used to measure how well Protara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -0.54. In addition to that, Return On Capital Employed is expected to decline to -0.63. At present, Protara Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 16.9 M, whereas Net Tangible Assets are forecasted to decline to about 71.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lisa MD | Seres Therapeutics | 65 | |
| Eddie MBA | Lumos Pharma | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Nicole Esq | HCW Biologics | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| RPh Young | Seres Therapeutics | 57 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Lee Flowers | HCW Biologics | 78 | |
| MD MBA | Eliem Therapeutics | 50 | |
| John PharmD | Scpharmaceuticals | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| MD FAAP | Lumos Pharma | N/A | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.28 |
Protara Therapeutics Leadership Team
Elected by the shareholders, the Protara Therapeutics' board of directors comprises two types of representatives: Protara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protara. The board's role is to monitor Protara Therapeutics' management team and ensure that shareholders' interests are well served. Protara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA MPH, VP CoFounder | ||
| Jesse Shefferman, Principal CoFounder | ||
| Jathin MD, Executive Officer | ||
| Justine OMalley, Senior Affairs | ||
| Kristine Rosse, VP Officer | ||
| Patrick MBA, Chief Officer | ||
| Hannah Fry, Principal Controller | ||
| Mary Grendell, General Secretary |
Protara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | (29.52 M) | ||||
| Shares Outstanding | 20.63 M | ||||
| Shares Owned By Insiders | 6.12 % | ||||
| Shares Owned By Institutions | 51.10 % | ||||
| Number Of Shares Shorted | 2.74 M | ||||
| Price To Book | 0.58 X | ||||
| EBITDA | (43.27 M) | ||||
| Net Income | (40.42 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.